Abstract
Evidence from clinical and experimental studies indicate that oxidative stress is involved in pathogenesis of Parkinson’s disease. The present study was designed to investigate the neuroprotective potential of lycopene on oxidative stress and neurobehavioral abnormalities in rotenone induced PD. Rats were treated with rotenone (3 mg/kg body weight, intraperitoneally) for 30 days. NADH dehydrogenase a marker of rotenone action was observed to be significantly inhibited (35%) in striatum of treated animals. However, lycopene administration (10 mg/kg, orally) to the rotenone treated animals for 30 days increased the activity by 39% when compared to rotenone treated animals. Rotenone administration increased the MDA levels (75.15%) in striatum, whereas, lycopene administration to rotenone treated animals decreased the levels by 24.33%. Along with this, significant decrease in GSH levels (42.69%) was observed in rotenone treated animals. Lycopene supplementation on the other hand, increased the levels of GSH by 75.35% when compared with rotenone treated group. The activity of SOD was inhibited by 69% in rotenone treated animals and on lycopene supplementation; the activity increased by 12% when compared to controls. This was accompanied by cognitive and motor deficits in rotenone administered animals, which were reversed on lycopene treatment. Lycopene treatment also prevented release of cytochrome c from mitochondria. Collectively, these observations suggest that lycopene supplementation along with rotenone for 30 days prevented rotenone-induced alterations in antioxidants along with the prevention of rotenone induced oxidative stress and neurobehavioral deficits. The results provide an evidence for beneficial effect of lycopene supplementation in rotenone-induced PD and suggest therapeutic potential in neurodegenerative diseases involving accentuated oxidative stress.
Similar content being viewed by others
Abbreviations
- PD:
-
Parkinson’s disease
- MDA:
-
Malondialdehyde
- SOD:
-
Superoxide dismutase
- GSH:
-
Glutathione
- AChE:
-
Acetylcholinesterase
- GPx:
-
Glutathione peroxidase
- PMS:
-
Post mitochondrial supernatant
- CAT:
-
Catalase
- H2O2 :
-
Hydrogen peroxide
- DTNB:
-
5,5′ Dithio-bis-2-nitrobenzoate
- ROS:
-
Reactive oxygen species
- RNS:
-
Reactive nitrogen species
- AD:
-
Alzheimer’s disease
References
Hald A, Lotharius J (2005) Oxidative stress and inflammation in Parkinson’s disease: is there a causal link? Exp Neurol 193:279–290
Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R (2007) How common are the “common” neurologic disorders? Neurology 68:326–337
Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79:368–376
Maj MC, Tkachyova I, Patel P, Addis JB, Mackay N, Levandovskiy V, Lee J, Lang AE, Cameron JM, Robinson BH (2010) Oxidative stress alters the regulatory control of p66Shc and Akt in PINK1 deficient cells. Biochem Biophys Res Commun 399:331–335
Stocchi F, Olanow CW (2003) Neuroprotection in Parkinson’s disease: clinical trials. Ann Neurol 53(Suppl 3):S87–97 discussion S97-89
Beal MF (2001) Experimental models of Parkinson’s disease. Nat Rev Neurosci 2:325–334
Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909
Alam M, Schmidt WJ (2002) Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 136:317–324
Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3:1301–1306
Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT (2003) Mechanism of toxicity in rotenone models of Parkinson’s disease. J Neurosci 23:10756–10764
Chen L, Ding Y, Cagniard B, Van Laar AD, Mortimer A, Chi W, Hastings TG, Kang UJ, Zhuang X (2008) Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 28:425–433
Weinreb O, Amit T, Mandel S, Youdim MB (2009) Neuroprotective molecular mechanisms of (−)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr 4:283–296
Wang MS, Boddapati S, Emadi S, Sierks MR (2010) Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson’s disease cell model. BMC Neurosci 11:57
Lu KT, Ko MC, Chen BY, Huang JC, Hsieh CW, Lee MC, Chiou RY, Wung BS, Peng CH, Yang YL (2008) Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J Agric Food Chem 56:6910–6913
Kamat CD, Gadal S, Mhatre M, Williamson KS, Pye QN, Hensley K (2008) Antioxidants in central nervous system diseases: preclinical promise and translational challenges. J Alzheimers Dis 15:473–493
Conn PF, Schalch W, Truscott TG (1991) The singlet oxygen and carotenoid interaction. J Photochem Photobiol B 11:41–47
Miller NJ, Sampson J, Candeias LP, Bramley PM, Rice-Evans CA (1996) Antioxidant activities of carotenes and xanthophylls. FEBS Lett 384:240–242
Mortensen A, Skibsted LH, Sampson J, Rice-Evans C, Everett SA (1997) Comparative mechanisms and rates of free radical scavenging by carotenoid antioxidants. FEBS Lett 418:91–97
Muzandu K, Ishizuka M, Sakamoto KQ, Shaban Z, El Bohi K, Kazusaka A, Fujita S (2006) Effect of lycopene and beta-carotene on peroxynitrite-mediated cellular modifications. Toxicol Appl Pharmacol 215:330–340
Srinivasan M, Sudheer AR, Pillai KR, Kumar PR, Sudhakaran PR, Menon VP (2007) Lycopene as a natural protector against gamma-radiation induced DNA damage, lipid peroxidation and antioxidant status in primary culture of isolated rat hepatocytes in vitro. Biochim Biophys Acta 1770:659–665
Sengupta A, Das S (1999) The anti-carcinogenic role of lycopene, abundantly present in tomato. Eur J Cancer Prev 8:325–330
Gerster H (1997) The potential role of lycopene for human health. J Am Coll Nutr 16:109–126
Shukla SK, Gupta S, Ojha SK, Sharma SB (2010) Cardiovascular friendly natural products: a promising approach in the management of CVD. Nat Prod Res 24:873–898
Sesso HD, Buring JE, Norkus EP, Gaziano JM (2004) Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in women. Am J Clin Nutr 79:47–53
Wei Y, Shen X, Shen H, Mai J, Wu M, Yao G (2010) Effects of lycopene on cerebral ischemia-reperfusion injury in rats. Wei Sheng Yan Jiu 39:201–204
Hsiao G, Fong TH, Tzu NH, Lin KH, Chou DS, Sheu JR (2004) A potent antioxidant, lycopene, affords neuroprotection against microglia activation and focal cerebral ischemia in rats. In Vivo 18:351–356
Sandhir R, Mehrotra A, Kamboj SS (2010) Lycopene prevents 3-nitropropionic acid-induced mitochondrial oxidative stress and dysfunctions in nervous system. Neurochem Int 57:579–587
Kumar P, Kalonia H, Kumar A (2009) Lycopene modulates nitric oxide pathways against 3-nitropropionic acid-induced neurotoxicity. Life Sci 85:711–718
Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358
Kono Y (1978) Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys 186:189–195
Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–77
Whittaker M (1984) Cholinesterases. In: Bergmeyer HU (ed) Methods of enzymatic analysis. Academic Press, New York, pp 52–74
Perez-Pinzon MA, Xu GP, Born J, Lorenzo J, Busto R, Rosenthal M, Sick TJ (1999) Cytochrome C is released from mitochondria into the cytosol after cerebral anoxia or ischemia. J Cereb Blood Flow Metab 19:39–43
Itoh J, Nabeshima T, Kameyama T (1991) Utility of an elevated plus-maze for dissociation of amnesic and behavioral effects of drugs in mice. Eur J Pharmacol 194:71–76
Allbutt HN, Henderson JM (2007) Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson’s disease. J Neurosci Methods 159:195–202
Beal MF (1998) Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta 1366:211–223
Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita SP, Wu JF, Carney JM et al (1995) Brain regional correspondence between Alzheimer’s disease histopathology and biomarkers of protein oxidation. J Neurochem 65:2146–2156
Adams JD Jr, Chang ML, Klaidman L (2001) Parkinson’s disease—redox mechanisms. Curr Med Chem 8:809–814
Navarro A, Boveris A (2009) Brain mitochondrial dysfunction and oxidative damage in Parkinson’s disease. J Bioenerg Biomembr 41:517–521
Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT (2002) An in vitro model of Parkinson’s disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 22:7006–7015
Koutsilieri E, Scheller C, Grunblatt E, Nara K, Li J, Riederer P (2002) Free radicals in Parkinson’s disease. J Neurol 249(Suppl 2):ll1–ll5
Adams JD Jr, Odunze IN (1991) Oxygen free radicals and Parkinson’s disease. Free Radic Biol Med 10:161–169
Singh C, Ahmad I, Kumar A (2007) Pesticides and metals induced Parkinson’s disease: involvement of free radicals and oxidative stress. Cell Mol Biol (Noisy-le-grand) 53:19–28
Wertz K, Siler U, Goralczyk R (2004) Lycopene: modes of action to promote prostate health. Arch Biochem Biophys 430:127–134
Matos HR, Di Mascio P, Medeiros MH (2000) Protective effect of lycopene on lipid peroxidation and oxidative DNA damage in cell culture. Arch Biochem Biophys 383:56–59
Kweon GR, Marks JD, Krencik R, Leung EH, Schumacker PT, Hyland K, Kang UJ (2004) Distinct mechanisms of neurodegeneration induced by chronic complex I inhibition in dopaminergic and non-dopaminergic cells. J Biol Chem 279:51783–51792
Cai J, Yang J, Jones DP (1998) Mitochondrial control of apoptosis: the role of cytochrome c. Biochim Biophys Acta 1366:139–149
Marella M, Seo BB, Yagi T, Matsuno-Yagi A (2009) Parkinson’s disease and mitochondrial complex I: a perspective on the Ndi1 therapy. J Bioenerg Biomembr 41:493–497
Jain A, Martensson J, Stole E, Auld PA, Meister A (1991) Glutathione deficiency leads to mitochondrial damage in brain. Proc Natl Acad Sci USA 88:1913–1917
Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD (1997) Alterations in the distribution of glutathione in the substantia nigra in Parkinson’s disease. J Neural Transm 104:661–677
Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52:381–389
Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348–355
Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B (1997) A generalised increase in protein carbonyls in the brain in Parkinson’s but not incidental Lewy body disease. J Neurochem 69:1326–1329
Kudin AP, Bimpong-Buta NY, Vielhaber S, Elger CE, Kunz WS (2004) Characterization of superoxide-producing sites in isolated brain mitochondria. J Biol Chem 279:4127–4135
Wei H, Meng Z (2010) Epigallocatechin-3-gallate protects Na + channels in rat ventricular myocytes against sulfite. Cardiovasc Toxicol 10:166–173
Alshatwi AA, Al Obaaid MA, Al Sedairy SA, Al-Assaf AH, Zhang JJ, Lei KY (2010) Tomato powder is more protective than lycopene supplement against lipid peroxidation in rats. Nutr Res 30:66–73
Bose KS, Agrawal BK (2007) Effect of lycopene from cooked tomatoes on serum antioxidant enzymes, lipid peroxidation rate and lipid profile in coronary heart disease. Singapore Med J 48:415–420
Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305:626–629
Gao W, Pu Y, Luo KQ, Chang DC (2001) Temporal relationship between cytochrome c release and mitochondrial swelling during UV-induced apoptosis in living HeLa cells. J Cell Sci 114:2855–2862
Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, Blessed G, Fairbairn A, Tomlinson BE, Perry RH (1985) Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 48:413–421
Melo JB, Agostinho P, Oliveira CR (2003) Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide. Neurosci Res 45:117–127
Pillay R, Maharaj DS, Daniel S, Daya S (2003) Acetylcholine reduces cyanide-induced superoxide anion generation and lipid peroxidation in rat brain homogenates. Prog Neuropsychopharmacol Biol Psychiatry 27:61–64
van Laar T, De Deyn PP, Aarsland D, Barone P, Galvin JE (2010) Effects of cholinesterase inhibitors in Parkinson’s disease dementia: a review of clinical data. CNS Neurosci Ther [Epub ahead of print]
Gabelli C (2003) Rivastigmine: an update on therapeutic efficacy in Alzheimer’s disease and other conditions. Curr Med Res Opin 19:69–82
Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT (2009) A highly reproducible rotenone model of Parkinson’s disease. Neurobiol Dis 34:279–290
McNamara P, Durso R, Harris E (2007) “Machiavellianism” and frontal dysfunction: evidence from Parkinson’s disease. Cogn Neuropsychiatry 12:285–300
Acknowledgments
The authors acknowledge the financial assistance received from the Department of Science of Technology and the University Grants Commission under the PURSE and SAP programs.
Conflict of interest
There is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kaur, H., Chauhan, S. & Sandhir, R. Protective Effect of Lycopene on Oxidative Stress and Cognitive Decline in Rotenone Induced Model of Parkinson’s Disease. Neurochem Res 36, 1435–1443 (2011). https://doi.org/10.1007/s11064-011-0469-3
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-011-0469-3